Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
화요일, 9월 01

Agilon Health Inc

AGLNYSE
Trade with Public
Trade with Public
$87.89
-4.65-5.02%
가까이에: Aug 31, 5:00 PM EST
$89.43
1.541.75%
시간외: 4:21 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Agilon Health Financials

Agilon Health (AGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: Agilon Health Sees Q3 Sales $1.445B-$1.475B vs $1.415B Est

Agilon Health (NYSE:AGL) sees Q3 sales of $1.445 billion-$1.475 billion vs $1.415 billion analyst estimate.
Benzinga Newsdesk

PRO
CORRECTION: Agilon Health Raises FY2026 Sales Guidance from $5.680B-$5.805B to $5.775B-$5.860B vs $5.719B Est

Agilon Health (NYSE:AGL) raises FY2026 sales outlook from $5.680 billion-$5.805 billion to $5.775 billion-$5.860 billion vs $5.719 billion estimate.
Benzinga Newsdesk

PRO
Agilon Health Q2 EPS $1.04 Beats $(0.75) Estimate, Sales $1.495B Beat $1.450B Estimate

Agilon Health (NYSE:AGL) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $(0.75) by 238.67 percent. This is a 116.64 percent increase over losses of $(6.25) per share from the
Benzinga Newsdesk

Dow Tumbles Over 300 Points: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

The CNN Money Fear and Greed index declined but remained in the Greed zone on Thursday. US stocks fell, some reported higher earnings.
Avi Kapoor

Agilon Health Operational Initiatives Begin Showing Results

Agilon Health shares surge after Q1 earnings beat, raised 2026 outlook, and stronger medical margins offset membership declines.
Vandana Singh

PRO
Agilon Health Raises FY2026 Sales Guidance from $5.410B-$5.580B to $5.680B-$5.805B vs $5.452B Est

Agilon Health (NYSE:AGL) raises FY2026 sales outlook from $5.410 billion-$5.580 billion to $5.680 billion-$5.805 billion vs $5.452 billion estimate.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved